Hypo-Stream Ltd is an emerging pharmaceutical company based in Cambridge, UK, specializing in the development of novel therapeutics for acute and chronic epithelial diseases, antimicrobial resistance, and respiratory conditions. Led by a team of experienced clinicians, world-class scientists, and seasoned pharmaceutical industry professionals, Hypo-Stream is dedicated to finding effective treatments for challenging medical conditions. Their clinical focus includes addressing acute inflammatory diseases, such as severe reactions to insect bites, acute asthma attacks, dermatitis flares, acute respiratory distress syndrome (ARDS), sepsis, burns, gunshot wounds, and post-surgical inflammatory responses.

By developing innovative solutions, they aim to provide a different approach to effective treatment for these life-threatening conditions. Additionally, Hypo-Stream is committed to tackling the surging problem of antimicrobial resistance, which poses a significant threat to public health. They aim to develop therapies that overcome the barrier of antibiotic resistance and contribute to reducing mortality rates from infections, as well as improving surgical outcomes.

In the field of burns, Hypo-Stream aims to improve survival rates and healing outcomes for patients with severe burns. Their goal is to minimize the need for multiple surgeries, lifelong scarring, and long stays in intensive care, thus reducing healthcare costs and improving patient recovery times. For more information and to get in touch with Hypo-Stream Pharmaceuticals, visit their website